Dizal Pharma Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 1,009

Employees

  • Stock Symbol
  • 688192

Stock Symbol

  • Share Price
  • $9.61
  • (As of Friday Closing)

Dizal Pharma General Information

Description

Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Jinghui East Road
  • Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District
  • Wuxi City, Jiangsu 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Jinghui East Road
  • Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District
  • Wuxi City, Jiangsu 201203
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dizal Pharma Stock Performance

As of 13-Nov-2026, Dizal Pharma’s stock price is $9.61. Its current market cap is $4.47B with 465M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.61 $9.76 $5.28 - $10.31 $4.47B 465M 6.37M $1.08

Dizal Pharma Financials Summary

As of 30-Sep-2026, Dizal Pharma has a trailing 12-month revenue of $723M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,968,325 3,673,668 2,386,862 2,657,307
Revenue 723,143 111,403 50,157 12,903
EBITDA 505,155 (93,075) (118,846) (146,730)
Net Income 501,208 (106,246) (117,896) (156,570)
Total Assets 992,087 429,135 235,440 211,096
Total Debt 192,506 177,334 158,544 57,892
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dizal Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dizal Pharma‘s full profile, request access.

Request a free trial

Dizal Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development,
Drug Discovery
Wuxi City, China
1,009 As of 2025

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dizal Pharma Competitors (1)

One of Dizal Pharma’s competitors is Shanghai Henlius, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Shanghai Henlius Formerly VC-backed Shanghai, China
You’re viewing 1 of 1 competitors. Get the full list »

Dizal Pharma Patents

Dizal Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024255634-A1 Pharmaceutical forms of quinazoline erbb inhibitors Pending 14-Apr-2023
EP-4695249-A1 Pharmaceutical forms of quinazoline erbb inhibitors Pending 14-Apr-2023
WO-2024213045-A1 Pharmaceutical forms of quinazoline erbb inhibitors Inactive 14-Apr-2023
AU-2023335416-A1 Egfr inhibitors and uses thereof Pending 02-Sep-2022
EP-4581036-A1 Egfr inhibitors and uses thereof Pending 02-Sep-2022 C07D498/22
To view Dizal Pharma’s complete patent history, request access »

Dizal Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dizal Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dizal Pharma‘s full profile, request access.

Request a free trial

Dizal Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Dizal Pharma’s complete esg history, request access »

Dizal Pharma FAQs

  • When was Dizal Pharma founded?

    Dizal Pharma was founded in 2017.

  • Where is Dizal Pharma headquartered?

    Dizal Pharma is headquartered in Wuxi City, China.

  • What is the size of Dizal Pharma?

    Dizal Pharma has 1,009 total employees.

  • What industry is Dizal Pharma in?

    Dizal Pharma’s primary industry is Drug Discovery.

  • Is Dizal Pharma a private or public company?

    Dizal Pharma is a Public company.

  • What is Dizal Pharma’s stock symbol?

    The ticker symbol for Dizal Pharma is 688192.

  • What is the current stock price of Dizal Pharma?

    As of 13-Nov-2026 the stock price of Dizal Pharma is $9.61.

  • What is the current market cap of Dizal Pharma?

    The current market capitalization of Dizal Pharma is $4.47B.

  • What is Dizal Pharma’s current revenue?

    The trailing twelve month revenue for Dizal Pharma is $723M.

  • Who are Dizal Pharma’s competitors?

    Shanghai Henlius is a competitor of Dizal Pharma.

  • What is Dizal Pharma’s annual earnings per share (EPS)?

    Dizal Pharma’s EPS for 12 months was $1.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process